Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236119 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis
A Phase 2 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00236119 is a Phase 2 study that has completed, run by Cephalon. The registered enrollment target is 46 participants.
The verdict
NCT00236119, a Phase 2 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients with Severe, Recalcitrant, Plaque Type Psoriasis.
Interventions
- DRUG CEP-701 20mg
- DRUG CEP-701 40mg
- DRUG CEP-701 60mg
- DRUG CEP-701 80mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00236119
The ClinicalTrials.gov registry entry for NCT00236119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CEP-701 20mg is the first listed.
NCT00236119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00236119 about?
NCT00236119 is a clinical study titled "Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis". A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients with Severe, Recalcitrant, Plaque Type Psoriasis.
What is the current status of trial NCT00236119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2005-06. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00236119?
The interventions under investigation include: CEP-701 20mg (DRUG), CEP-701 40mg (DRUG), CEP-701 60mg (DRUG), CEP-701 80mg (DRUG).
Who is sponsoring clinical trial NCT00236119?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.